Hansoh Pharma/GSK: Ris‑Rez meets PFS endpoint in China phase III ARTEMIS‑011 (relapsed osteosarcoma)

Key highlights
  • ARTEMIS‑011, a China phase III trial, met its primary endpoint of progression‑free survival versus chemotherapy in patients with osteosarcoma who progressed or relapsed after ≥2 prior systemic lines.
  • Consistent benefit was reported across secondary endpoints, including overall survival, and no new safety signals were identified.
  • Ris‑Rez (risvutatug rezetecan) is a B7‑H3‑targeted antibody‑drug conjugate; Hansoh will use the data for regulatory submission in China.
  • GSK holds exclusive rights to develop and commercialise Ris‑Rez outside mainland China, Hong Kong, Macau and Taiwan and is advancing the global EMBOLD Sarcoma‑202 trial.

Trial result

Hansoh Pharmaceutical's ARTEMIS‑011 phase III trial in China evaluating risvutatug rezetecan (Ris‑Rez) in patients with osteosarcoma who progressed or relapsed after at least two prior systemic therapies met its primary endpoint of progression‑free survival (PFS), showing statistically significant and clinically meaningful improvements versus chemotherapy.

Efficacy and safety

Consistent benefit was observed across secondary endpoints, including overall survival. The safety profile was consistent with prior findings in this tumour type and no new safety signals were identified. Hansoh intends to use these data for regulatory submission in China.

Development status

Ris‑Rez is a B7‑H3‑targeted antibody‑drug conjugate composed of a fully human anti‑B7‑H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. GSK acquired exclusive rights to develop and commercialise Ris‑Rez outside mainland China, Hong Kong, Macau and Taiwan and is advancing EMBOLD Sarcoma‑202, a global phase Ib/II study in previously treated unresectable advanced or metastatic sarcomas, including osteosarcoma. Ris‑Rez has US FDA Breakthrough Therapy Designation in relapsed or refractory osteosarcoma.

Clinical context

Osteosarcoma mainly affects children and young adults and accounts for 20–40% of primary bone cancers. It is a rare disease with a global incidence of approximately 3.4 cases per million people per year. After progression on two prior lines of treatment, therapeutic options are severely limited and no approved therapies exist for that setting.

Source: GSK

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

26 October 2026
Hansoh/GSK: Ris‑Rez cuts progression or death risk by 67% vs chemotherapy in relapsed osteosarcoma (China phase III)

Phase III ARTEMIS‑011 showed median PFS 5.5 vs 1.4 months (HR 0.33); safety showed high rates of grade ≥3 TRAEs with Ris‑Rez versus chemotherapy.

23 October 2026
GSK Mo‑Rez shows 62% confirmed response and 12.2‑month median DoR in platinum‑resistant ovarian cancer

Phase Ib BEHOLD‑1 reports durable responses and 11.1‑month median PFS at the selected phase III dose; safety predominantly haematologic with most grade ≥3 events.

18 October 2026
GSK reports global phase Ib Ris‑Rez data in relapsed extensive‑stage SCLC

Phase Ib shows 61% ORR at 8 mg/kg with manageable safety; data supported selection of 8 mg/kg for the ongoing global phase III EMBOLD SCLC‑301.

16 October 2026
GSK presents new Ris‑Rez, Mo‑Rez and Jemperli data at ESMO 2026

More than 20 abstracts across lung, gynaecological and gastrointestinal cancers, including positive Ris‑Rez ES‑SCLC activity, Mo‑Rez durable responses in platinum‑resistant ovarian cancer, and Jemperli complete responses in MSI‑H rectal cancer.

13 September 2026
GSK/Hansoh: Ris‑Rez halves death risk vs topotecan in relapsed SCLC in China

Ris‑Rez extended median OS to 18.5 vs 10.3 months (HR 0.46) and showed improved PFS, response rates and fewer grade ≥3 TRAEs versus topotecan.